New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 17, 2013
13:17 EDTATHXAthersys receives stem cell trial approval in U.K.
Athersys announced that the Medicines and Healthcare products Regulatory Agency has approved Athersys' application to expand its ongoing Phase 2 study evaluating the administration of MultiStem therapy to patients who have suffered an ischemic stroke. Enrollment at United Kingdom sites is expected to commence following final Ethics Committee review and the completion of final preparations at participating clinical centers. "The MHRA authorization will enable us to bring several leading United Kingdom stroke centers into the study, which will help us to speed the completion of the stroke clinical trial," said Dr. Gil Van Bokkelen, chairman and CEO of Athersys. "The authorization is also noteworthy as it marks the initiation of MultiStem clinical development activity in the United Kingdom."
News For ATHX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2015
05:40 EDTATHXAthersys: MAPC effective in improving health of animals after acute rodent SCI
Athersys announced that multipotent adult progenitor cells, or MAPC, used in Athersys' MultiStem cell therapy currently in clinical development, are effective in improving the health of animals after acute rodent spinal cord injury. Intravenous administration of MAPC one day after injury prevented loss of spinal cord tissue resulting in significant improvement of walking function and urinary control. "The results described in this important publication build on and are consistent with previously completed preclinical and clinical studies in acute neurological injuries, including the Phase 2 study in ischemic stroke," commented Dr. Robert Mays, Senior Vice President and Head of Neurosciences at Athersys. "The data show consistent mechanisms of action for MultiStem in targeting and modulating the immune system, and enhancing recovery and repair. Importantly, these results support our belief that the intravenous administration of MultiStem may lead to durable and substantial benefits in humans, which is consistent with our clinical observations in other programs. Athersys commends the outstanding work of Jerry Silver's lab at Case Western Reserve University School of Medicine, and we look forward to additional progress that will enable the clinical translation of this therapy for spinal cord injured patients." This study provides additional strong support for the use of MultiStem as a therapeutic for human acute spinal cord injury with the overall goals of improving quality of life, motor control, and reducing long-term patient care costs.
November 16, 2015
13:09 EDTATHXAthersys management to meet with Maxim
Meeting to be held in London on November 18 hosted by Maxim.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use